Johnson & Johnson (NYSE:JNJ)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $123.45 and last traded at $123.31, with a volume of 2,392,636 shares traded. The stock had previously closed at $122.85.

A number of equities analysts have issued reports on JNJ shares. Argus raised their target price on Johnson & Johnson from $116.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, April 20th. Goldman Sachs Group Inc. restated a “neutral” rating and set a $114.00 target price (up previously from $112.00) on shares of Johnson & Johnson in a report on Wednesday, April 20th. Royal Bank Of Canada raised their target price on Johnson & Johnson from $114.00 to $122.00 and gave the stock an “outperform” rating in a report on Friday, April 15th. Leerink Swann restated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 20th. Finally, Societe Generale started coverage on Johnson & Johnson in a report on Wednesday, April 6th. They set a “hold” rating and a $113.00 target price on the stock. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $112.59.

The firm has a market capitalization of $338.11 billion and a P/E ratio of 22.40. The company has a 50-day moving average of $117.22 and a 200 day moving average of $109.26.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 19th. The company reported $1.68 EPS for the quarter, beating the consensus estimate of $1.65 by $0.03. The business had revenue of $17.50 billion for the quarter, compared to the consensus estimate of $17.50 billion. During the same quarter in the previous year, the company earned $1.56 EPS. The firm’s revenue for the quarter was up .6% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post $6.61 earnings per share for the current fiscal year.

In other Johnson & Johnson news, VP Gary J. Pruden sold 9,735 shares of the stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $116.03, for a total value of $1,129,552.05. Following the transaction, the vice president now owns 43,630 shares in the company, valued at $5,062,388.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Ronald A. Kapusta sold 3,957 shares of the stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $114.77, for a total value of $454,144.89. Following the completion of the transaction, the chief accounting officer now owns 29,682 shares in the company, valued at approximately $3,406,603.14. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Heritage Wealth Advisors raised its position in shares of Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock valued at $1,021,000 after buying an additional 317 shares during the last quarter. S. R. Schill & Associates raised its position in shares of Johnson & Johnson by 122.7% in the fourth quarter. S. R. Schill & Associates now owns 11,110 shares of the company’s stock valued at $1,141,000 after buying an additional 6,121 shares during the last quarter. Lourd Capital LLC raised its position in shares of Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock valued at $1,142,000 after buying an additional 851 shares during the last quarter. Eidelman Virant Capital raised its position in shares of Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock valued at $1,193,000 after buying an additional 1,231 shares during the last quarter. Finally, Vigilant Capital Management LLC raised its position in shares of Johnson & Johnson by 1.8% in the fourth quarter. Vigilant Capital Management LLC now owns 11,838 shares of the company’s stock valued at $1,216,000 after buying an additional 210 shares during the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.